Related Experiment Video
Updated: Jun 13, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Experience with sorafenib and adverse event management
Joaquim Bellmunt1, Timothy Eisen, Mayer Fishman
1Solid Tumor Oncology Section, Medical Oncology Service, University Hospital del Mar-IMIM, Barcelona, Spain. jbellmunt@imas.imim.es
Critical Reviews in Oncology/Hematology
|April 20, 2010
Summary
Sorafenib improves progression-free survival in advanced renal cell cancer (RCC) but causes more adverse events. Expert recommendations guide managing side effects like rash and hypertension to optimize treatment.
Area of Science:
- Oncology
- Pharmacology
Background:
- Sorafenib is a multikinase inhibitor approved for advanced renal cell cancer (RCC).
- The TARGET trial demonstrated sorafenib's efficacy in improving progression-free survival compared to placebo.
- Higher incidence of adverse events necessitates effective management strategies.
Purpose of the Study:
- To provide expert recommendations for managing common sorafenib-related adverse events in advanced RCC.
- To outline strategies for mitigating the frequency and severity of these side effects.
- To optimize sorafenib therapy for patients with advanced RCC.
Main Methods:
- Expert panel discussion in February 2009.
- Review of adverse event management in advanced RCC patients treated with sorafenib.
- Development of recommendations for specific toxicities and dose modifications.
Main Results:
- Sorafenib offers a progression-free survival advantage in advanced RCC.
- Adverse events, including skin rash, hand-foot skin reaction, diarrhea, and hypertension, are more frequent with sorafenib.
- Management guidelines and dose modification strategies were developed.
Conclusions:
- Effective management of sorafenib-induced adverse events is crucial for patient quality of life.
- Implementing recommended strategies can optimize sorafenib treatment outcomes in advanced RCC.
- These recommendations aim to balance efficacy and tolerability for RCC patients.
Related Concept Videos
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:16Kidney Transplant III: Nursing Management
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...